Haematology

Doç. Dr. Mesut Tığlıoğlu

Doctor and researcher Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi İstanbul
Lymphoma, Large B-Cell, DiffuseLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lymphoma, Large B-Cell, Diffuse 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyHaematologysaglik.gov.trFrom source
  • InstitutionGöztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesisaglik.gov.trFrom source
  • Area of workLymphoma, Large B-Cell, DiffuseExtracted from 2 publications · Model version —From source
  • Publications43 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0002-4111-2004ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://suleymanyalcinsh.saglik.gov.tr/TR-1493237/doktorlarimiz.html#mesut-tiglioglusaglik.gov.tr

Scientific work

Publications on Lymphoma, Large B-Cell, Diffuse

43 publications
Publications by year Most: 18, in 2021
  1. 2019: 4 publications
  2. 2020: 5 publications
  3. 2021: 18 publications
  4. 2022: 9 publications
  5. 2023: 1 publication
  6. 2024: 1 publication
  7. 2025: 1 publication
  8. 2026: 4 publications

  1. 2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group

    Clinical Lymphoma Myeloma and Leukemia, 2026

    DOI 10.1016/j.clml.2026.08.008 PMID 42705998 Source: ORCID

  2. Real-world effectiveness and safety of fixed-duration frontline venetoclax–obinutuzumab for chronic lymphocytic leukemia: A nationwide multicenter retrospective cohort study

    Leukemia Research, 2026

    DOI 10.1016/j.leukres.2026.108342 PMID 42933070 Source: OpenAlex

  3. Ferritin and LDH predict thrombotic risk beyond conventional scoring systems in DLBCL

    Annals of Hematology, 2026

    DOI 10.1007/s00277-026-07201-y PMID 42897372 Open-access full textSource: ORCID

  4. PA-211 Gastric Extramedullary Disease as the Initial Manifestation of IgA Kappa Multiple Myeloma with Rapid Fatal Progression

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)03578-0 Source: OpenAlex

  5. SMOLDERING MULTIPLE MYELOMA, DIAGNOSIS AND MANAGEMENT

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-694-3_p9 Source: OpenAlex

  6. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia

    Clinical Lymphoma Myeloma and Leukemia, 2024

    DOI 10.1016/j.clml.2023.12.015 PMID 38342726 7 citations (Europe PMC) Source: ORCID

  7. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkısh oncology group study

    Journal of Cancer Research and Therapeutics, 2023

    DOI 10.4103/jcrt.jcrt_355_22 PMID 37147993 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  8. Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

    Journal of Hematopathology, 2022

    DOI 10.1007/s12308-022-00488-6 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  9. Marjinal Zon Lenfoma Tanılı Hastalarda Klinik Özellikler ve Olası Prognostik Faktörler: İki Merkezden Retrospektif Analiz

    LLM Dergi, 2022

    DOI 10.5578/llm.20229903 Open-access full textSource: OpenAlex

  10. The impact of hematological parameters on survival for patients with COVID-19

    Ahi Evran Medical Journal, 2022

    DOI 10.46332/aemj.1014259 Open-access full textSource: OpenAlex

View all 43 publications